* . *
  • About
  • Advertise
  • Privacy & Policy
  • Contact
Tuesday, September 23, 2025
Earth-News
  • Home
  • Business
  • Entertainment
    Why Hilaria Baldwin Has Found the ‘DWTS’ Process ‘Embarrassing’ At Times – WFXG

    Hilaria Baldwin Opens Up About the Embarrassing Moments on Her ‘DWTS’ Journey

    Harvest Fest 2025 – yadkinripple.com

    Celebrate the Bounty: Harvest Fest 2025 is Coming!

    Fox News Entertainment Newsletter: Kate Middleton stuns during Trump state visit, Brett James dead at 57 – Fox News

    Kate Middleton Stuns During Trump State Visit; Remembering Brett James at 57

    Lara Beitz to headline Oshkosh show with top comedians at Time Community Theater Sept. 27 – Yahoo

    Lara Beitz to Headline Star-Studded Oshkosh Comedy Night on September 27

    Shakespeare (with a twist) in Grand Junction – Yahoo

    Experience Shakespeare Like Never Before in Grand Junction

    Congress Bill Spotlight: Make Entertainment Great Again (MEGA) Act, Renaming Kennedy Center to Trump Center – The Fulcrum

    Congress Proposes MEGA Act to Rename Kennedy Center as Trump Center and Revitalize Entertainment

  • General
  • Health
  • News

    Cracking the Code: Why China’s Economic Challenges Aren’t Shaking Markets, Unlike America’s” – Bloomberg

    Trump’s Narrow Window to Spread the Truth About Harris

    Trump’s Narrow Window to Spread the Truth About Harris

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Trending Tags

    • Trump Inauguration
    • United Stated
    • White House
    • Market Stories
    • Election Results
  • Science
  • Sports
  • Technology
    Agentic AI and the future of work: navigating technological promise and the risk of increased automation – Equal Times

    Agentic AI and the Future of Work: Embracing Innovation While Navigating Automation Challenges

    Technology alliance introduces system for stable recycling quality – RECYCLING magazine

    Innovative Technology Alliance Unveils Breakthrough System for Consistent Recycling Quality

    Pepper Pike council considers upgrading technology for streaming meetings, remote meeting participation – Cleveland.com

    Pepper Pike Council Explores Upgrading Technology for Enhanced Streaming and Remote Participation

    How Michelin Uses Technology to Rethink Tire Manufacturing: Interview – Motor1.com

    How Michelin’s Tech-Driven Revolution Is Transforming Tire Manufacturing

    Analysts Offer Insights on Technology Companies: Avnet (AVT), Nvidia (NVDA) and Atlassian (TEAM) – The Globe and Mail

    Experts Share Key Insights on Avnet, Nvidia, and Atlassian’s Future Prospects

    Top Technology Executives Recognized at the 2025 Carolina CIO ORBIE Awards – Yahoo Finance

    Celebrating Excellence: Top Technology Executives Honored at the 2025 Carolina CIO ORBIE Awards

    Trending Tags

    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • Mark Zuckerberg
No Result
View All Result
  • Home
  • Business
  • Entertainment
    Why Hilaria Baldwin Has Found the ‘DWTS’ Process ‘Embarrassing’ At Times – WFXG

    Hilaria Baldwin Opens Up About the Embarrassing Moments on Her ‘DWTS’ Journey

    Harvest Fest 2025 – yadkinripple.com

    Celebrate the Bounty: Harvest Fest 2025 is Coming!

    Fox News Entertainment Newsletter: Kate Middleton stuns during Trump state visit, Brett James dead at 57 – Fox News

    Kate Middleton Stuns During Trump State Visit; Remembering Brett James at 57

    Lara Beitz to headline Oshkosh show with top comedians at Time Community Theater Sept. 27 – Yahoo

    Lara Beitz to Headline Star-Studded Oshkosh Comedy Night on September 27

    Shakespeare (with a twist) in Grand Junction – Yahoo

    Experience Shakespeare Like Never Before in Grand Junction

    Congress Bill Spotlight: Make Entertainment Great Again (MEGA) Act, Renaming Kennedy Center to Trump Center – The Fulcrum

    Congress Proposes MEGA Act to Rename Kennedy Center as Trump Center and Revitalize Entertainment

  • General
  • Health
  • News

    Cracking the Code: Why China’s Economic Challenges Aren’t Shaking Markets, Unlike America’s” – Bloomberg

    Trump’s Narrow Window to Spread the Truth About Harris

    Trump’s Narrow Window to Spread the Truth About Harris

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Trending Tags

    • Trump Inauguration
    • United Stated
    • White House
    • Market Stories
    • Election Results
  • Science
  • Sports
  • Technology
    Agentic AI and the future of work: navigating technological promise and the risk of increased automation – Equal Times

    Agentic AI and the Future of Work: Embracing Innovation While Navigating Automation Challenges

    Technology alliance introduces system for stable recycling quality – RECYCLING magazine

    Innovative Technology Alliance Unveils Breakthrough System for Consistent Recycling Quality

    Pepper Pike council considers upgrading technology for streaming meetings, remote meeting participation – Cleveland.com

    Pepper Pike Council Explores Upgrading Technology for Enhanced Streaming and Remote Participation

    How Michelin Uses Technology to Rethink Tire Manufacturing: Interview – Motor1.com

    How Michelin’s Tech-Driven Revolution Is Transforming Tire Manufacturing

    Analysts Offer Insights on Technology Companies: Avnet (AVT), Nvidia (NVDA) and Atlassian (TEAM) – The Globe and Mail

    Experts Share Key Insights on Avnet, Nvidia, and Atlassian’s Future Prospects

    Top Technology Executives Recognized at the 2025 Carolina CIO ORBIE Awards – Yahoo Finance

    Celebrating Excellence: Top Technology Executives Honored at the 2025 Carolina CIO ORBIE Awards

    Trending Tags

    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • Mark Zuckerberg
No Result
View All Result
Earth-News
No Result
View All Result
Home Health

New Trials in Leukemia/Lymphoma: Could Your Patient Benefit?

February 29, 2024
in Health
New Trials in Leukemia/Lymphoma: Could Your Patient Benefit?
Share on FacebookShare on Twitter

Several clinical trials in leukemia and lymphoma have started enrolling recently. Maybe one of your patients could benefit from taking part?

Hematological malignancy scheduled for a human leukocyte antigen–mismatched unrelated donor transplant. Adult patients in this situation who are younger than 66 years may be eligible for a randomized, open-label, phase 2 study run by the Center for International Blood and Bone Marrow Transplant Research.

The purpose of the study is to test whether cyclophosphamide, which is given to prevent a dreaded complication of stem cell transplantation called graft-versus-host disease, can be safely reduced without increasing infection or reducing protection. All participants will receive cyclophosphamide on days 3 and 4 post transplant. One group will receive a reduced dose of cyclophosphamide (25 mg/kg per dose), and the other will be given a usual dose (37.5 mg/kg).

Sites in Michigan, Missouri, Oregon, Virginia, and Washington started recruiting for 190 participants in December 2023. Study centers in Florida, Massachusetts, New York, and Wisconsin are also planned. Infection-free survival is the primary endpoint, and overall survival is a secondary measure. Quality of life (QoL) is not recorded. More details at clinicaltrials.gov

Untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Adults who are newly diagnosed with this type of cancer and have active disease may wish to consider a randomized, open-label, phase 3 trial testing an experimental Bruton tyrosine kinase (BTK) inhibitor, nemtabrutinib (from Merck Sharp & Dohme), against standard-of-care BTK inhibitors ibrutinib (Imbruvica) and acalabrutinib (Calquence).

BTK inhibitors target B-cell proliferation in B-cell cancers such as CLL/SLL and allow for chemotherapy-free treatment of some hematological malignancies. In this study, until disease progression, unacceptable toxicity, or another reason for discontinuation occurs, participants will take daily oral nemtabrutinib, ibrutinib, or acalabrutinib.

The study opened in December 2023 in Pennsylvania, Washington, Taiwan, Israel, and the United Kingdom seeking 1200 participants. The primary outcomes are objective response rate and progression-free survival. Overall survival is a secondary outcome, and QoL is not measured. More details at clinicaltrials.gov

Relapsed or refractory leukemia with a KMT2A-gene rearrangement (KMT2A-r). Children aged 1 month to younger than 6 years with this diagnosis may be able to join an open-label, nonrandomized, Children’s Oncology Group phase 2 study to determine the most tolerable and/or effective dose of an experimental oral drug called revumenib when added to chemotherapy.

KMT2A-gene alterations are associated with a poor prognosis in leukemia. These alterations cause blood cells to dedifferentiate and start proliferating uncontrollably as leukemia cells. The expression of the damaged KMT2A gene relies on a protein called menin. Revumenib, from Syndax Pharmaceuticals, blocks menin and prevents expression of KMT2A.

Children in the study will receive two different regimens of revumenib in combination with chemotherapy for up to a year, or until disease progression or unacceptable toxicity, and will then be followed for up to 5 years. Trial centers in 12 US states opened their doors in January 2024 looking for 78 participants. Toxicities and minimal residual disease are the primary outcomes; overall survival is a secondary outcome, and QoL is not assessed. More details at clinicaltrials.gov

Previously untreated follicular lymphoma or diffuse large B-cell lymphoma. Adults with one of these types of lymphoma may be eligible for one of three open-label, randomized, phase 3 trials testing odronextamab (from Regeneron). This bispecific antibody is designed to ‘lock together’ CD20 on cancer cells with CD3-expressing cancer-killing T cells. It has shown anti-lymphoma activity in heavily pretreated patients.

Late in 2023, three phase 3 trials turned the spotlight on treatment-naive patients and started recruiting 2115 participants to assess odronextamab in this setting. The trial OLYMPIA-1 will compare odronextamab with standard-of-care rituximab (Rituxan) plus chemotherapy in follicular lymphoma. OLYMPIA-2 will test the drug in combination with chemotherapy, also in follicular lymphoma. OLYMPIA-3 will evaluate odronextamab plus chemotherapy against rituximab and chemotherapy in people with large B-cell lymphoma.

All study drugs, including odronextamab, will be administered by intravenous infusion, and participants will be followed for up to 5 years. Research centers across eight US states and Australia, Czechia, France, Italy, Poland, Spain, Turkey, and Thailand are currently accepting participants for the three trials. The primary outcomes are various measures of toxicity and complete response at 30 months in the follicular lymphoma studies and toxicity and progression-free survival in large B-cell lymphoma. All three trials are measuring overall survival and QoL as secondary endpoints.

Previously untreated stage II, III, or IV follicular lymphoma. Adults with this type of cancer may be eligible to participate in a randomized, open-label, phase 3 study testing whether an experimental therapy called epcoritamab (from AbbVie) improves disease response and is tolerable when added to standard therapy. For up to 120 weeks, one group of participants will receive a combination of intravenous rituximab and oral lenalidomide (Revlimid), while a second group will also receive subcutaneous injections of epcoritamab. Some participants may be offered investigators’ choice of chemotherapy as well.

Sites across Iowa, Maryland, Missouri, Ohio, Washington, and Montana started welcoming their 900 participants in February 2024. The primary outcome is complete response at 30 months. Overall survival and QoL are secondary outcomes. More details at clinicaltrials.gov

Relapsed or refractory mantle cell lymphoma. Adults facing one of these clinical scenarios can join an Academic and Community Cancer Research United open label, phase 2 trial examining the effectiveness of combining tafasitamab (Monjuvi), lenalidomide, and venetoclax (Venclexta) for such patients.

Frontline therapy does not cure mantle cell lymphoma, and continued relapses are common. In this situation, treatments can include acalabrutinib, ibrutinib, stem cell transplantation, venetoclax, lenalidomide, and rituximab.

In this study, participants will take venetoclax and lenalidomide daily and receive intravenous tafasitamab every 2 weeks after an initial ramp-up period as per clinic standards. Participants will be followed for 5 years after entering the trial. The Mayo Clinic in Rochester, Minnesota, began recruiting the planned 100 trial participants in January 2024. The primary outcome is objective response rate; overall survival is a secondary outcome, and QoL will not be tracked. More details at clinicaltrials.gov

All trial information is from the National Institutes of Health US National Library of Medicine (online at clinicaltrials.gov).

>>> Read full article>>>
Copyright for syndicated content belongs to the linked Source : Medscape – https://www.medscape.com/viewarticle/new-trials-leukemia-and-lymphoma-could-your-patient-benefit-2024a10003vq

Tags: healthLeukemiaTrials
Previous Post

Michigan’s ‘uncommitted’ voters send warning sign to President Biden

Next Post

Few Pediatricians Comfortable Treating Youth With OUD

FOCUS | SCIO holds press conference on promoting high-quality development through high-level ecological & environmental protection – Xinhua

FOCUS | SCIO holds press conference on promoting high-quality development through high-level ecological & environmental protection – Xinhua

September 23, 2025
Researcher on Tylenol-Autism Connection: Not the Best Science – Managed Healthcare Executive

Researcher Questions the Science Behind Tylenol-Autism Link

September 23, 2025
Da Vinci’s Genetic Secrets May Soon Be Revealed by Ambitious DNA Project – ScienceAlert

Unlocking Da Vinci’s Genetic Mysteries: The Ambitious DNA Project Set to Reveal All

September 23, 2025
Eco-Chic Home & Lifestyle Design Market Is Booming Worldwide | Major Giants The Joinery, Emeco, Greenington – openPR.com

Eco-Chic Home & Lifestyle Design Market Is Booming Worldwide | Major Giants The Joinery, Emeco, Greenington – openPR.com

September 23, 2025
Agentic AI and the future of work: navigating technological promise and the risk of increased automation – Equal Times

Agentic AI and the Future of Work: Embracing Innovation While Navigating Automation Challenges

September 23, 2025
Viking Sports Weekly September 22 – csuvikings.com

Viking Sports Weekly September 22 – csuvikings.com

September 23, 2025
Dynamic Pricing is Fair Play for the 2026 FIFA World Cup – Cato Institute

How Dynamic Pricing Will Revolutionize the 2026 FIFA World Cup Experience

September 22, 2025
White House Touts Rising Confidence In U.S. Economy Under Trump’s Second Term – Yahoo

White House Celebrates Rising Optimism in U.S. Economy Amid Trump’s Second Term

September 22, 2025
Why Hilaria Baldwin Has Found the ‘DWTS’ Process ‘Embarrassing’ At Times – WFXG

Hilaria Baldwin Opens Up About the Embarrassing Moments on Her ‘DWTS’ Journey

September 22, 2025
New Tech Ally Ready to Fight Against Chronic Health Conditions – Sutter Health

Revolutionary Tech Partner Set to Transform the Fight Against Chronic Health Conditions

September 22, 2025

Categories

Archives

September 2025
MTWTFSS
1234567
891011121314
15161718192021
22232425262728
2930 
« Aug    
Earth-News.info

The Earth News is an independent English-language daily published Website from all around the World News

Browse by Category

  • Business (20,132)
  • Ecology (832)
  • Economy (852)
  • Entertainment (21,730)
  • General (17,189)
  • Health (9,895)
  • Lifestyle (865)
  • News (22,149)
  • People (855)
  • Politics (862)
  • Science (16,063)
  • Sports (21,352)
  • Technology (15,835)
  • World (836)

Recent News

FOCUS | SCIO holds press conference on promoting high-quality development through high-level ecological & environmental protection – Xinhua

FOCUS | SCIO holds press conference on promoting high-quality development through high-level ecological & environmental protection – Xinhua

September 23, 2025
Researcher on Tylenol-Autism Connection: Not the Best Science – Managed Healthcare Executive

Researcher Questions the Science Behind Tylenol-Autism Link

September 23, 2025
  • About
  • Advertise
  • Privacy & Policy
  • Contact

© 2023 earth-news.info

No Result
View All Result

© 2023 earth-news.info

No Result
View All Result

© 2023 earth-news.info

Go to mobile version